EAM
RVMD icon

Eventide Asset Management’s Revolution Medicines RVMD Stock Holding History

Eventide Asset Management’s Portfolio RVMD Stock Details RVMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$42.7M Sell
227,845
-33,580
-13% -$4.9M 0.57% 56
2026
Q1 		$25.4M Sell
261,425
-116,836
-31% -$11.8M 0.42% 85
2025
Q4 		$30.1M Sell
378,261
-216,777
-36% -$14.2M 0.47% 78
2025
Q3 		$27.8M Buy
595,038
+222,809
+60% +$8.72M 0.46% 82
2025
Q2 		$13.7M Hold
372,229
– – 0.24% 112
2025
Q1 		$13.2M Hold
372,229
– – 0.26% 112
2024
Q4 		$16.3M Sell
372,229
-150,822
-29% -$7.61M 0.3% 105
2024
Q3 		$23.7M Sell
523,051
-127,775
-20% -$5.56M 0.41% 76
2024
Q2 		$25.3M Buy
650,826
+289,826
+80% +$10.8M 0.43% 74
2024
Q1 		$11.6M Hold
361,000
– – 0.18% 117
2023
Q4 		$10.4M Hold
361,000
– – 0.17% 119
2023
Q3 		$9.99M Buy
361,000
+365
+0.1% +$10.8K 0.18% 122
2023
Q2 		$9.65M Buy
+360,635
New +$8.85M 0.16% 120

Other funds holding RVMD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.76B AUM 342.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

Eventide Asset Management's RVMD Position: Q2 2026 in Review

Eventide Asset Management reduced its Revolution Medicines (RVMD) stake by 13% in Q2 2026, selling an estimated $4.9M and leaving 227,845 shares worth $42.7M. The position accounts for 0.57% of the portfolio, ranked #56.

Eventide Asset Management first reported a position in RVMD in Q2 2023 and has held it in 13 quarters since. 690 funds tracked by Wall St. Rank hold RVMD as of Q2 2026.

  • Eventide Asset Management held 227,845 shares of Revolution Medicines worth $42.7M as of Q2 2026.
  • Eventide Asset Management sold 33,580 Revolution Medicines shares in Q2 2026, an estimated $4.9M.
  • Revolution Medicines made up 0.57% of Eventide Asset Management's portfolio in Q2 2026, its #56 holding.
  • Eventide Asset Management first reported a position in Revolution Medicines in Q2 2023 and has held it in 13 quarters since.
  • 690 funds tracked by Wall St. Rank held Revolution Medicines as of Q2 2026.

Based on Eventide Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.